Amphastar Pharmaceuticals, INC 10-Q quarterly reports

Amphastar Pharmaceuticals reported a 5% increase in net revenues for Q2 2026, reaching $183.9 million, but faced higher costs and an FDA warning letter for its IMS subsidiary.

Amphastar Pharmaceuticals reports mixed Q1 2026 results with revenue flat, but gross profit down 18% due to increased costs and pricing pressures.

Amphastar Pharmaceuticals reports mixed Q3 2025 results with strong BAQSIMI sales growth offset by increased litigation expenses and declines in other key products.

Amphastar Pharmaceuticals reports a decline in net income and total revenues for Q2 2025, driven by product mix changes and increased operating expenses, despite strong BAQSIMI growth.

Amphastar Pharmaceuticals' Q1 2025 results show a slight decrease in total net revenues but a significant increase in BAQSIMI sales following the assumption of full global distribution.

Amphastar Pharmaceuticals saw a revenue increase in Q3 2024, driven by the integration of BAQSIMI and growth in key product sales, despite some margin pressures.

Amphastar Pharmaceuticals saw a significant increase in revenue and profitability in the second quarter of 2024, driven by the acquisition of BAQSIMI and strong performance in key product lines.

Amphastar Pharmaceuticals saw a significant increase in revenue and net income in the first quarter of 2024, driven by strong product sales and the acquisition of BAQSIMI.